Development of antibody-siRNA conjugate targeted to cardiac and skeletal muscles.


Despite considerable efforts to develop efficient carriers, the major target organ of short-interfering RNAs (siRNAs) remains limited to the liver. Expanding the application outside the liver is required to increase the value of siRNAs. Here we report on a novel platform targeted to muscular organs by conjugation of siRNAs with anti-CD71 Fab' fragment. This… (More)
DOI: 10.1016/j.jconrel.2016.06.036